Associations - BRCA1 mutation

BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	bevacizumab + olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	rucaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	rucaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	bevacizumab + olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	niraparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	niraparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	rucaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	bevacizumab + olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Fallopian Tube Cancer Fallopian Tube Cancer	BGB-290 Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	niraparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	talazoparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BGB-290 Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	rucaparib Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Peritoneal Cancer Peritoneal Cancer	BGB-290 Sensitive: A1 - Approval
BRCA1 mutation BRCA1 mutation	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	bevacizumab Resistant: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	talazoparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	cisplatin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	carboplatin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	capecitabine Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	vinorelbine tartrate Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	eribulin mesylate Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pegylated liposomal doxorubicin Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	olaparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	talazoparib Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	doxorubicin hydrochloride Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	paclitaxel Sensitive: A2 - Guideline
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	niraparib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	CaT Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib + cediranib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	trabectedin Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	PARP inhibitor Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	ABT-888 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	SHR 3162 Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	ribociclib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	talazoparib Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	atezolizumab Resistant: B - Late Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	CPB Sensitive: B - Late Trials
BRCA1 mutation BRCA1 mutation	Non Small Cell Lung Cancer NSCLC	rucaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Cholangiocarcinoma Cholangiocarcinoma	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	rucaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	niraparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Mesothelioma Mesothelioma	rucaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Germ Cell Tumors Germ Cell Tumors	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	rucaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	BGB-290 Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	talazoparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Colorectal Cancer CRC	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	talazoparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Renal Cell Carcinoma RCC	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	niraparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	olaparib Sensitive: C1 - Off-label
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	tislelizumab + BGB-290 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	ABT-888 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Serous Adenocarcinoma Ovarian Serous Adenocarcinoma	olaparib + LY2606368 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib + CP-675206 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	bevacizumab + olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	IMP4297 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	SC10914 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Breast Cancer Breast Cancer	olaparib + AZD5363 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	olaparib + durvalumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	tislelizumab + BGB-290 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	olaparib + durvalumab + CP-675206 Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Solid Tumor Solid Tumor	avelumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	carboplatin + paclitaxel Sensitive: C2 – Inclusion Criteria
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	gemcitabine + eribulin mesylate Resistant: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab + niraparib Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PARP inhibitor Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	olaparib + AZD6738 Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	fulvestrant + anastrozole Resistant: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	FOLFIRINOX Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Ovarian Cancer Ovarian Cancer	BAY1895344 Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Pancreatic Cancer Pancreatic Cancer	oxaliplatin Sensitive: C3 – Early Trials
BRCA1 mutation BRCA1 mutation	Endometrial Cancer Endometrial Cancer	rucaparib + sacituzumab govitecan-hziy Sensitive: C3 – Early Trials